An appraisal of the scientific current situation and new perspectives in the treatment of cutaneous leishmaniasis
| Autor: | José María Bermúdez, María Fernanda García-Bustos, Analía I. Romero, Alicia Graciela Cid, C.A. Briones Nieva, Mercedes Villegas |
|---|---|
| Rok vydání: | 2021 |
| Předmět: |
0301 basic medicine
medicine.medical_specialty Veterinary (miscellaneous) 030231 tropical medicine Leishmaniasis Cutaneous Drug resistance Genus: Leishmania 03 medical and health sciences 0302 clinical medicine Cutaneous leishmaniasis medicine Humans Intensive care medicine Leishmaniasis Pharmaceutical industry Leishmania Vaccines business.industry Neglected Diseases 030108 mycology & parasitology medicine.disease Vaccination Infectious Diseases Pharmaceutical Preparations Insect Science Chemoprophylaxis Neglected tropical diseases Parasitology business |
| Zdroj: | Acta tropica. 221 |
| ISSN: | 1873-6254 |
| Popis: | Leishmaniasis is a Neglected Tropical Diseases caused by protozoan parasites of the genus Leishmania. It is a major health problem in many tropical and subtropical regions of the world and can produce three different clinical manifestations, among which cutaneous leishmaniasis has a higher incidence in the world than the other clinical forms. There are no recognized and reliable means of chemoprophylaxis or vaccination against infections with different forms of leishmaniasis. In addition, chemotherapy, unfortunately, remains, in many respects, unsatisfactory. Therefore, there is a continuing and urgent need for new therapies against leishmaniasis that are safe and effective in inducing a long-term cure. This review summarizes the latest advances in currently available treatments and improvements in the development of drug administration. In addition, an analysis of the in vivo assays was performed and the challenges facing promising strategies to treat CL are discussed. The treatment of leishmaniasis will most likely evolve into an approach that uses multiple therapies simultaneously to reduce the possibility of developing drug resistance. There is a continuous effort to discover new drugs to improve the treatment of leishmaniasis, but this is mainly at the level of individual researchers. Undoubtedly, more funding is needed in this area, as well as greater participation of the pharmaceutical industry to focus efforts on the development of chemotherapeutic agents and vaccines for this and other neglected tropical diseases. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|
Full Text from ScienceDirect